Disc Medicine (IRON) Stock Price, News & Analysis

Company Overview

Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for disorders of iron dysregulation. Iron homeostasis plays a central role in a broad spectrum of diseases, including iron overload conditions such as hereditary hemochromatosis and iron-restricted anemias driven by chronic inflammation. Disc Medicine applies proprietary antibody discovery platforms to target key proteins involved in iron transport and storage, with the goal of restoring balanced iron levels in patients who suffer from life-threatening complications of iron imbalance.

The company’s lead program is an investigational monoclonal antibody that targets ferroportin, the only known cellular iron exporter, to modulate iron egress from cells and reduce systemic iron overload. This candidate, currently in early-stage clinical studies, is being evaluated for safety, tolerability and preliminary signs of activity in patients with hereditary and secondary iron overload. In parallel, Disc Medicine is advancing a second antibody program designed to neutralize hepcidin, the master regulator of iron sequestration, with the aim of alleviating anemia of inflammation in chronic disease settings.

Headquartered in South San Francisco, Disc Medicine was founded by a multidisciplinary team of scientists and clinicians with deep expertise in iron biology, antibody engineering and translational medicine. The company completed its initial public offering in 2022 and trades on the Nasdaq under the ticker IRON. Disc Medicine continues to expand its research capabilities, forging collaborations with academic centers and patient-advocacy groups to support the development of therapies for underserved populations affected by iron dysregulation disorders.

Key Stats

• Today's Range: $57.43 to $62.00
• 50-Day Range: $45.12 to $58.00
• 52-Week Range: $30.82 to $68.73
• Volume: 672,319 shs
• Average Volume: 342,608 shs
• Market Capitalization: $2.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $96.70
• Consensus Rating: Buy

Disc Medicine Stock Analysis - MarketRank™

Disc Medicine scored higher than 67% of companies evaluated by MarketBeat, and ranked 331st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Disc Medicine has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Disc Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Disc Medicine is -14.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Disc Medicine is -14.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Disc Medicine has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.58% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Disc Medicine has recently decreased by 4.06%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Disc Medicine does not currently pay a dividend.

Dividend Growth

Disc Medicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.58% of the float of Disc Medicine has been sold short.

Short Interest Ratio / Days to Cover

Disc Medicine has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Disc Medicine has recently decreased by 4.06%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.37

News Sentiment

Disc Medicine has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Disc Medicine this week, compared to 6 articles on an average week.

Search Interest

7 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.

MarketBeat Follows

2 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,140,575.00 in company stock.

Percentage Held by Insiders

Only 4.24% of the stock of Disc Medicine is held by insiders.

Percentage Held by Institutions

83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IRON Stock Analysis - Frequently Asked Questions

How have IRON shares performed this year?

Disc Medicine's stock was trading at $63.40 at the start of the year. Since then, IRON shares have decreased by 8.9% and is now trading at $57.77.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) announced its earnings results on Wednesday, May, 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by $0.03.

Who are Disc Medicine's major shareholders?

Disc Medicine's top institutional investors include Atle Fund Management AB (0.07%) and Avanza Fonder AB. Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Kevin Bitterman, Mona Ashiya, John D Quisel, Pamela Stephenson, Jean M Franchi, William Jacob Savage, Jonathan Yen-Wen Yu, Rahul Khara, Brian Richard Macdonald, Joanne Bryce and William Richard White.
View institutional ownership trends.

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Disc Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/20/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IRON
• CIK: 1816736
• Web: www.discmedicine.com
• Phone: 617-401-4400
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Disc Medicine: $96.70
• High Price Target: $132.00
• Low Price Target: $75.00
• Potential Upside/Downside: +67.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$109.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -22.61%
• Return on Assets: -21.07%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 37.65
• Quick Ratio: 37.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.85 per share
• Price / Book: 3.89

Miscellaneous

• Outstanding Shares: 34,630,000
• Free Float: 33,166,000
• Market Cap: $2.00 billion
• Optionable: Not Optionable
• Beta: 0.76